2,3-Bis-(3,4Dimethoxy-phenyl)-acrylonitrile

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2,3-Bis-(3,4Dimethoxy-phenyl)-acrylonitrile
• 英文别名: 2,3-bis-(3,4-dimethoxyphenyl)acrylonitrile；2,3-bis(3,4-dimethoxyphenyl)prop-2-enenitrile
• 化学式: C₁₉H₁₉NO₄
• 分子量: 325.364
• InChiKey: AJPJIPYVXWDABV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  60.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-Bis-(3,4Dimethoxy-phenyl)-acrylonitrile 在 二异丁基氢化铝 、 氯化铵 作用下， 以 水 、 N,N-二甲基甲酰胺 、 甲苯 、 苯 为溶剂， 反应 6.0h， 生成 3,4-bis(3,4-dimethoxyphenyl)-1H-pyrrole
  参考文献：
  名称：

  A Paal–Knorr Approach to 3,4-Diaryl-Substituted Pyrroles: Facile Synthesis of Lamellarins O and Q

  摘要：

  A very simple, yet efficient synthetic methodology, to obtain 3,4-diaryl-substituted pyrroles is described. The approach is based on the Knoevenagel condensation between arylacetonitriles and substituted aromatic aldehydes, followed by conjugate addition of cyanide to afford succinonitriles in excellent yields. The products thus obtained were subjected to DIBAL-H reduction, followed by cyclization under acidic conditions to produce the corresponding pyrroles in good overall yields. The utility of this protocol is exemplified by the synthesis of the marine alkaloids lamellarins O and Q.

  DOI：

  10.1055/s-0032-1317351
• 作为产物：
  描述：

  3,4-二甲氧基苯乙腈 、 3,4-二甲氧基苯甲醛 在 sodium 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 2,3-Bis-(3,4Dimethoxy-phenyl)-acrylonitrile
  参考文献：
  名称：

  DIBENZO[f,h]ISOQUINOLINE DERIVATIVES

  摘要：

  一组新型的二苯并[f,h]异喹啉衍生物，如规范中所示。还公开了使用这些化合物治疗与NO过度产生、癌症或病毒感染相关的疾病的方法。

  公开号：

  US20110172261A1

文献信息

• PHENANTHROINDOLIZIDINE ANALOGUES
  申请人：Lee Shiow-Ju

  公开号：US20100216773A1

  公开（公告）日：2010-08-26

  Treatment of coronavirus infection with phenanthroindolizidine analogues.

  使用菲南三氮杂环吲哚啉类似物治疗冠状病毒感染。
• Process of preparing discotic liquid crystalline compounds
  申请人：Merck Patent Gesellschaft

  公开号：US06534135B1

  公开（公告）日：2003-03-18

  The invention relates to a process of preparing a discotic liquid crystalline compound by intramolecular oxidative cyclisation of a diaryl compound in an organic solvent in the presence of a strong acid, characterized in that an oxidative agent comprising a chrom(VI)oxide derivative is used, to discotic liquid crystalline compounds obtainable from said process, to liquid crystalline media, (co)polymers or polymer networks with columnar phases comprising said discotic liquid crystalline compounds, and to the use of said discotic liquid crystalline compounds, liquid crystalline media or liquid crystalline (co)polymers with columnar phases for liquid crystal displays, optical elements like polarizers, compensators or colour filters, chemical sensors, charge transport materials, optical storage media, nonlinear optics, decorative pigments, adhesive or synthetic resins with anisotropic mechanical properties.

  该发明涉及一种通过在有机溶剂中在强酸存在下对二芳基化合物进行分子内氧化环化制备片状液晶化合物的方法，其特征在于使用包含铬（VI）氧化物衍生物的氧化剂，以获得从该方法中可获得的片状液晶化合物、液晶介质、（共）聚合物或具有包含所述片状液晶化合物的柱状相的聚合物网络，以及使用所述片状液晶化合物、液晶介质或具有柱状相的液晶（共）聚合物用于液晶显示器、偏振器、补偿器或彩色滤光片、化学传感器、电荷传输材料、光学存储介质、非线性光学、装饰性颜料、具有各向异性机械性能的粘合剂或合成树脂。
• DIBENZO[f,h]ISOQUINOLINE DERIVATIVES
  申请人：Lee Shiow-Ju

  公开号：US20110172261A1

  公开（公告）日：2011-07-14

  A group of novel dibenzo[f,h]isoquinoline derivatives as shown in the specification. Also disclosed are methods of using the compounds for treating a disease associated with NO overproduction, cancer, or viral infection.

  一组新型的二苯并[f,h]异喹啉衍生物，如规范中所示。还公开了使用这些化合物治疗与NO过度产生、癌症或病毒感染相关的疾病的方法。
• Breast cancer resistance protein (bcrp) inhibitor
  申请人：Yamazaki Ryuta

  公开号：US20060128636A1

  公开（公告）日：2006-06-15

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH 3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR 1 (R 1 is hydrogen or C1-C4 alkyl), —O(CH 2 ) n COOR 2 (n=1−7: R 2 is hydrogen or C1-C4 alkyl), —OOCCH 2 CH 2 COOR 3 (R 3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH) 2 ) or a salt thereof, a sulfate group (i.e., —OSO 3 H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  本发明提供了一种抑制BCRP的药物。一种含有以下式（1）所表示的二苯乙烯腈衍生物作为活性成分的乳腺癌耐药蛋白抑制剂：[其中，8个R分别表示氢原子、羟基、硝基、氨基、乙酰氨基（—NHCOCH3基）、氰基（—CN基）、甲酰基（—CHO基）、—COOR1（R1为氢或C1-C4烷基）、—O（CH2）nCOOR2（n = 1-7：R2为氢或C1-C4烷基）、—OOCCH2CH2COOR3（R3为氢、C1-C4烷基、（Z）-2-（3,4-二甲氧基苯基）-3-（4-羟基苯基）-丙烯腈或葡萄糖基）、C1-C8烷氧基、C1-C4烷基、卤原子、C1-C4烷氧基C1-C4烷氧基C1-C4烷氧基、C2-C8酰氧基、C2-C8卤代酰氧基、亚甲二氧基基团、三氟甲基基团、磷酸酯基团（即—OP（O）（OH）2）或其盐、硫酸酯基团（即—OSO3H）或其盐、葡萄糖基或其盐、葡萄糖基的磷酸酯或酯的盐、葡萄糖基的硫酸酯或酯的盐，或者是它的酯或盐。
• STILBENE DERIVATIVE AND STILBENE ANALOG DERIVATIVE, AND USE THEREOF
  申请人：MORINAGA MILK INDUSTRY CO., LTD.

  公开号：EP0640586A1

  公开（公告）日：1995-03-01

  A compound with a 12-lipoxygenase inhibitor activity, represented by general formula (I), a precursor therefor, and a medicine containing the same, wherein R¹ represents hydrogen or hydroxy; one of R² and R³ represents hydrogen, while the other cyano; and Ar represents (a), (b) or (c), wherein R⁴ represents hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl or cyano.

  由通式（I）表示的具有 12-脂氧合酶抑制剂活性的化合物、其前体以及含有该化合物的药物，其中 R¹ 代表氢或羟基；R² 和 R³ 中的一个代表氢，另一个代表氰基；Ar 代表（a）、（b）或（c），其中 R⁴ 代表氢、低级烷基、低级烷氧基、卤素、三氟甲基或氰基。